Description
SEBI issues prohibitory order under Recovery Certificate No. 6156 of 2022 against Sampath Kumar Meesala (PAN: AIIPM9512D) in connection with Transgene Biotek Limited.
Summary
SEBI has issued a prohibitory order under Recovery Certificate No. 6156 of 2022 against Sampath Kumar Meesala (PAN: AIIPM9512D) in the matter of Transgene Biotek Limited. This order pertains to recovery proceedings for outstanding dues owed to SEBI.
Key Points
- Recovery Certificate No. 6156 of 2022 issued against Sampath Kumar Meesala
- PAN of the individual: AIIPM9512D
- Matter relates to Transgene Biotek Limited
- Prohibitory order issued to enforce recovery of dues
- Order published February 17, 2026 under SEBI’s enforcement/recovery proceedings
Regulatory Changes
No new regulatory changes introduced. This is an enforcement action under existing recovery mechanisms established by SEBI.
Compliance Requirements
- Sampath Kumar Meesala must comply with the recovery certificate and prohibitory order
- Outstanding dues to SEBI must be settled as per Recovery Certificate No. 6156 of 2022
- Non-compliance may result in further enforcement actions including attachment of assets
- Banks and financial institutions are directed not to allow disposal of assets belonging to the defaulter
Important Dates
- Recovery Certificate No.: 6156 of 2022
- Prohibitory Order Date: February 17, 2026
Impact Assessment
Market Impact: Low - This is an individual enforcement action with limited broader market implications.
Entity Impact: High for Sampath Kumar Meesala - Prohibitory measures restrict financial activities until recovery is completed.
Compliance Significance: This order demonstrates SEBI’s continued enforcement of recovery proceedings against individuals with outstanding dues from previous regulatory actions or penalties related to Transgene Biotek Limited.
Impact Justification
Enforcement action against a specific individual under recovery proceedings; limited broader market impact but significant for the individual and entity involved